Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
The recently announced P4 Healthcare relationship is an unprecedentedapproach to nutrition in the medical markets. Many of the largest privateoncology practices in the country will be preferentially offering RESURGEX(R)products to their patients, in their offices, beginning in Q4 of '07. Inaddition, the Resurgex line of products will be strategically marketed by P4in its professional Caring4Cancer journal and informative website,www.caring4cancer.com
After several successful clinical trials, Millennium will launch its newsports product SURGEX(TM) into the U.S. and International sports markets in Q4of '07. The response to the results of the trials as well as feedback onSURGEX(TM) from many professional strength and conditioning coaches andplayers, has been overwhelmingly positive, and sets the stage for a nationaland international launch.
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc.is a research-based nutraceutical company and a pioneer in the emerging fieldof specialized nutritional supplements. The company's flagship products,Resurgex(R), Resurgex Plus(R), and Resurgex Select(R), are designed to assistin reducing fatigue and oxidative stress, maintaining lean muscle and immunesupport in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary ofMillennium Biotechnologies Group, Inc., a publicly-traded company(OTC Bulletin Board: MBTG). For more information about MillenniumBiotechnologies, please contact Jerry Swon, Chief Executive Officer, email@example.com or call (908) 604-2500. For more information about theResurgex line of products visit http://www.resurgex.com.
This release includes certain forward-looking information that is basedupon management's beliefs as well as on assumptions made by and data currentlyavailable to management. This information which has been, or in the future maybe, included in reliance on the "safe harbor" provisions of the PrivateSecurities Litigation Reform Act of 1995, is subject to a number of risks anduncertainties, including but not limited to uncertainty as to marketacceptance of Resurgex and Resurgex Plus and the factors identified in theCompany's 10-KSB and other documents filed with the Securities and ExchangeCommission. Actual results may differ materially form those anticipated insuch forward-looking statements even if experience or future changes make itclear the any projected results expressed or implied therein may not berealized. The Company undertakes no obligation to update or revise anyforward-looking statements to reflect subsequent events or circumstances.
SOURCE Millennium Biotechnologies Group, Inc.
You May Also Like